



# Chapter 3: Treatment information

This chapter is part of a series of materials. For more information, and to access further materials, please visit [www.KEYTRUDA.co.uk](http://www.KEYTRUDA.co.uk)

## For patients being treated with KEYTRUDA<sup>®</sup> (pembrolizumab) in combination with axitinib for advanced renal cell carcinoma

Your healthcare team should have provided you with materials to help you identify any side effects you may experience on your treatment. Ensure you read the Patient Safety Information Brochure and carry your Patient Alert Card with you at all times.

It is important to be aware of side effects. Telling your healthcare professional straight away as soon as you notice any symptoms may stop them from becoming more serious.

**DO NOT ATTEMPT TO DIAGNOSE OR TREAT SIDE EFFECTS YOURSELF.**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (tel: 01992 467272). By reporting side effects you can help provide more information on the safety of this medicine.





# Treatment information

You may find it useful to fill in these details with the help of your nurse or healthcare provider:

Diagnosis:

Staging:

Date of diagnosis:

Treatment plan:

Planned start date:

Date of surgery:

Type of surgery:

Other treatment:



# Treatment information

You may find it useful to fill in these details with the help of your nurse or healthcare provider:

Surgeon:

Oncologist:

Clinical Nurse Specialist:

Concurrent medications:



# Treatment information

You may find it useful to fill in these details with the help of your nurse or healthcare provider:

Medication allergies and reactions:

Past medical history and previous treatments: